A New Antibody Treatment for Migraine

This editorial discusses the clinical trial by Ashina et al. on Lu AG09222, a monoclonal antibody targeting pituitary adenylate cyclase activating polypeptide (PACAP) for migraine prevention. While the trial demonstrated a modest reduction in migraine days (2 fewer days/month compared to placebo), the author highlights the significance of this proof of concept study, which validates PACAP as a new therapeutic target. The editorial compares Lu AG09222 to existing CGRP monoclonal antibodies, noting similar efficacy but emphasizing the need for diverse treatment options for non responders. Challenges such as equitable access, long term safety (particularly cardiovascular and pregnancy related effects), and the high cost of antibody therapies are critically examined. The piece underscores the importance of ensuring broader accessibility to advanced migraine treatments for underserved populations.

This editorial discusses the clinical trial by Ashina et al. on Lu AG09222, a monoclonal antibody targeting pituitary adenylate cyclase activating polypeptide (PACAP) for migraine prevention. While the trial demonstrated a modest reduction in migraine days (2 fewer days/month compared to placebo), the author highlights the significance of this proof of concept study, which validates PACAP as a new therapeutic target. The editorial compares Lu AG09222 to existing CGRP monoclonal antibodies, noting similar efficacy but emphasizing the need for diverse treatment options for non responders. Challenges such as equitable access, long term safety (particularly cardiovascular and pregnancy related effects), and the high cost of antibody therapies are critically examined. The piece underscores the importance of ensuring broader accessibility to advanced migraine treatments for underserved populations.